ClinicalTrials.gg
CompletedNCT01451632Updated Sep 8, 2016Results posted

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

A Phase 1 interventional study of MM-121 and Irinotecan in Colorectal Cancer, Squamous Cell Head and Neck Cancer and Non-small Cell Lung Cancer, sponsored by Merrimack Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-08.

Sponsored by Merrimack Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
105th of 185
48 · median 60
Started
2011
with 3 others
Phase 1
19 of 187
3 open now
Registered
93rd of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 105th largest by enrollment of the 185 interventional ones that give a count, is one of 4 that started in 2011, is one of 19 in phase 1, and was the 93rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

Read the detailed description

This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and irinotecan.

03

Conditions studied

  • Colorectal Cancer
  • Squamous Cell Head and Neck Cancer
  • Non-small Cell Lung Cancer
  • Triple Negative Breast Cancer
  • Other Tumors With EGFR Dependence

Keywords

  • Metastatic Colorectal cancer
  • Kras wild-type
  • Squamous cell head and neck cancer
  • Non-small cell lung cancer
  • Triple negative breast cancer
  • EGFR
  • ErbB3
  • MM-121
  • Cetuximab
  • Irinotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No standard options remaining
  • Adequate liver and kidney functions
  • 18 years of age or above

Exclusion criteria

Exclusion Criteria:

  • History of any secondary active cancer in the last 3 years.
  • Pregnant or breast feeding
  • History of severe allergic reactions or to cetuximab or irinotecan
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Part 1: MM-121 + cetuximab

    increasing doses of weekly MM-121 + weekly cetuximab

    Drug: MM-121 · Drug: Cetuximab

  • Experimental
    Part 2: MM-121 + cetuximab + irinotecan

    increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1

    Drug: MM-121 · Drug: Irinotecan · Drug: Cetuximab

Interventions

  • DrugMM-121

    escalating doses MM-121 IV QW

    Also known as: Seribantumab, SAR256212

  • 180 mg/m2 IV Q2W

    Also known as: Camptosar

  • escalating doses cetuximab IV QW

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination

    To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.

    Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks

  2. To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses

    Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2

    Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks

  3. To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan

    Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2

    Time frame: From date of first dose to 30 days after termination, the longest 48.1 weeks

Secondary outcomes

  1. Objective Response Rate

    To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.

    Time frame: Patients were assessed for objective response from time of first dose through treatment termination, the longest treatment duration being 48.1 weeks

  2. Pharmacokinetics

    Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)

    Time frame: Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121

  3. Pharmacokinetic Parameters of MM-121

    Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the AUClast. Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)

    Time frame: Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121

  4. Immunogenicity

    Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).

    Time frame: Samples were collected for all patients pre-dose on all cycles for duration of treatment, the longest of which was 48.1 weeks, and a collection was made post-infusion in any case of infusion reaction

07

Results

Posted Sep 8, 2016

Participant flow

Participant flow — Overall Study
MilestonePart 1: Cohort 1Part 1: Cohort 2aPart 1: Cohort 2bPart 1: Cohort 3aPart 1: Cohort 3bPart 1: Cohort 4Part 1: Expansion CohortPart 2: Cohort 1Part 2: Cohort 2Part 2: Expansion Cohort
Started8433448644
Completed8433448644
Not completed0000000000

Outcome measures

PrimaryDose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination

To establish the safety of escalating doses of MM-121 in combination with cetuximab or in combination with cetuximab and irinotecan in order to determine the recommended phase 2 dose.. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.

Time frame:
From date of first dose to 30 days after termination, the longest 48.1 weeks
Reported as:
Number · participants reporting DLTs
Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination
participants reporting DLTsPart 1: Cohort 1Part 1: Cohort 2aPart 1: Cohort 2bPart 1: Cohort 3aPart 1: Cohort 3bPart 1: Cohort 4Part 2: Cohort 1Part 2: Cohort 2
Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination10000012
PrimaryTo Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses

Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2

Time frame:
From date of first dose to 30 days after termination, the longest 48.1 weeks
Reported as:
Number · mg/kg
To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses
mg/kgPart 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + Irinotecan
MM-121 loading dose40NA
MM-121 maintenance dose2020
PrimaryTo Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan

Using a 3+3 dose escalation model, the maximum tolerated dose of each combination was determined by assessing dose-limiting toxicities in each cohort. RP2D = one dose lever lower than the MTD Part 1: Cohort 1: MM-121: 12 mg/kg MM-121 QW + Cetuximab: 400 mg/m2 loading dose/200 mg/m2 (400/200) QW maintenance Cohort 2a: MM-121: 20 mg/kg IV QW + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 2b: MM-121: 12 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 3a: MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW (40/20) + Cetuximab: 400 / 200 mg/m2 maintenance IV QW Cohort 3b: MM-121 20 mg/kg IV QW + Cetuximab: 400 /250 mg/m2 maintenance IV QW Cohort 4: MM-121: 40/20 mg/kg IV QW + Cetuximab: 400 / 250 mg/m2 maintenance IV QW Part 2: Cohort 1: MM-121: 20 mg/kg IV QW + Cetuximab: 400/200 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2 IV Q2W Cohort 2: MM-121: 40 / 20 mg/kg IV QW + Cetuximab: 400/250 mg/m2 maintenance IV QW + Irinotecan: 180 mg/m2

Time frame:
From date of first dose to 30 days after termination, the longest 48.1 weeks
Reported as:
Number · mg/m2
To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan
mg/m2Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + Irinotecan
Cetuximab loading dose400400
Cetuximab maintenance dose250250
IrinotecanNA180
SecondaryObjective Response Rate

To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response (PR) is defined as \>20% decrease in tumor burden from baseline and a Complete Response (CR) is defined as complete disappearance from tumor burden from baseline. Objective Response is presented as the total # patients with PR or CR.

Time frame:
Patients were assessed for objective response from time of first dose through treatment termination, the longest treatment duration being 48.1 weeks
Reported as:
Number · participants with objective response
Objective Response Rate
participants with objective responsePart 1: Cohort 1Part 1: Cohort 2aPart 1: Cohort 2bPart 1: Cohort 3aPart 1: Cohort 3bPart 1: Cohort 4Part 1: Expansion CohortPart 2: Cohort 1Part 2: Cohort 2Part 2: Expansion Cohort
Objective Response Rate1000001100
SecondaryPharmacokinetics

Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the maximum observed concentration (Cmax). Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)

Time frame:
Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121
Reported as:
Geometric mean · ug/mL
Pharmacokinetics
ug/mLPart 1: 12 mg/kgPart 1: 20 mg/kgPart 1: 40/20 mg/kgPart 2: 20 mg/kgPart 2: 40/20 mg/kg
Pharmacokinetics316.8 ± 23.6611.0 ± 45.8794.1 ± 58.2505.8 ± 10.21278.2 ± 25
SecondaryPharmacokinetic Parameters of MM-121

Pharmacokinetic (PK) evaluation was performed on plasma samples obtained weekly for the first six weeks of the study and then on day 1 of each additional cycle to assess pre-treatment trough concentrations of MM-121. Non-compartmental analysis (NCA) was performed to calculate standard PK parameters, including the AUClast. Serum levels of MM-121 were measured at a central lab using an enzyme-linked immunosorbent assay (ELISA). Data is presented per dose level of MM-121 (12 mg/kg, 20 mg/kg, or 40/20 mg/kg) and per study part (Part 1 or Part 2)

Time frame:
Collections taken for all patients at Cycle 1, Week 1 at pre-infusion, at the end of the infusion, and 2.5, 4, 6 and 24 hours after starting the infusion of MM-121
Reported as:
Geometric mean · hr* ug/mL
Pharmacokinetic Parameters of MM-121
hr* ug/mLPart 1: 12 mg/kgPart 1: 20 mg/kgPart 1: 40/20 mg/kgPart 2: 20 mg/kgPart 2: 40/20 mg/kg
Pharmacokinetic Parameters of MM-12124190.5 ± 22.053063.1 ± 46.191111.9 ± 39.947681.5 ± 14.298387.7 ± 16.2
SecondaryImmunogenicity

Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).

Time frame:
Samples were collected for all patients pre-dose on all cycles for duration of treatment, the longest of which was 48.1 weeks, and a collection was made post-infusion in any case of infusion reaction
Reported as:
Number
Immunogenicity
MeasurePart 1: Cohort 1Part 1: Cohort 2aPart 1: Cohort 2bPart 1: Cohort 3aPart 1: Cohort 3bPart 1: Cohort 4Part 1: Expansion CohortPart 2: Cohort 1Part 2: Cohort 2Part 2: Expansion Cohort
ImmunogenicityNANANANANANANANANANA

Adverse events

Collected over AEs were collected from a patient's first dose until 30 days after treatment termination. SAEs were collected from time of informed consent until 30 days after termination. If related, events could be reported at any time after termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: MM-121 + Cetuximab—15/34 (44.1%)34/34 (100%)
Part 2: MM-121 + Cetuximab + Irinotecan—6/14 (42.9%)14/14 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPart 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + Irinotecan
DiarrheaGastrointestinal disorders1/342/14
Intestinal ObstructionGastrointestinal disorders0/341/14
NauseaGastrointestinal disorders0/341/14
StomatitisGastrointestinal disorders0/341/14
VomitingGastrointestinal disorders0/341/14
Non-cardiac chest painGeneral disorders0/341/14
Urinary Tract InfectionInfections and infestations0/341/14
Pericardial effusionCardiac disorders1/341/14
Cardiac ArrestCardiac disorders0/341/14
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/341/14
Most frequent other events
Showing 10 of 99
Most frequent other events
EventPart 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + Irinotecan
DiarrheaGastrointestinal disorders17/3413/14
FatigueGeneral disorders22/349/14
HypokalemiaMetabolism and nutrition disorders10/349/14
NauseaGastrointestinal disorders8/348/14
Dermatitis AcneformSkin and subcutaneous tissue disorders18/344/14
HypomagnesemiaMetabolism and nutrition disorders18/345/14
Decreased AppetiteMetabolism and nutrition disorders12/347/14
Weight DecreasedInvestigations8/347/14
DehydrationMetabolism and nutrition disorders0/346/14
StomatitisGastrointestinal disorders9/345/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + IrinotecanTotal
Mean56.1 ± 14.1956.6 ± 11.3856.35 ± 12.79
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + IrinotecanTotal
Female13922
Male21526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + IrinotecanTotal
Hispanic or Latino213
Not Hispanic or Latino311344
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + IrinotecanTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American303
White261339
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Part 1: MM-121 + CetuximabPart 2: MM-121 + Cetuximab + IrinotecanTotal
United States341448
08

Study locations

4 sites
  • San Francisco, California 94115, United States
  • Boston, Massachusetts 02115, United States
  • Chapel Hill, North Carolina 27599, United States
  • Salt Lake City, Utah 84112, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2011
First posted
Oct 13, 2011
Start
Oct 2011
Primary completionActual
Nov 2013
CompletionActual
Jun 2014
Results first posted
Sep 8, 2016
Last update
Sep 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01451632
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 13, 2011
Start date
Oct 2011
Primary completion
Nov 2013
Completion
Jun 2014
Results posted
Sep 8, 2016
Last update
Sep 8, 2016

Study contacts

Victor Moyo, MD
study director · Merrimack Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Seribantumab · Cetuximab

Start the discussion